Insider buying last 90 days
No open-market insider purchases were filed for ATRC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ATRC insider filing, plotted on the chart in Gekko.Open ATRC in Gekko
NASDAQ: ATRC
AtriCure (ATRC) Stock Analysis & Forecast
Oct 12 close
$57.28+1.47 (+2.6%)
Gekko Brief
AI summaryOct 12 closeAtriCure has rallied sharply in recent weeks, and this week's coverage reflects debate over whether that move has run ahead of fundamentals. Second-quarter revenue of $153.6 million, ahead of forecasts, has drawn continued attention, alongside commentary describing a 70% three-month rally and questions about valuation, with one assessment calling shares significantly overvalued even as another cites an "above average" score and a breakout with no resistance above the current price. A filing also showed BlackRock disclosing a 15.4% stake in the company.
ATRC closed at $57.28, up 2.6%, and sits above both its 50-day average of $51.08 and 200-day average of $36.76, with the shorter average above the longer one, a configuration consistent with an established uptrend. The GekkoIndex reads 55.8, placing it in the Neutral zone. Price stands 9.8% above the Gekko Fair Value of $52.18, a gap flagged as a headwind in the current assessment.
Earnings are set for 4 November, 22 days out and within a typical 20-trading-day holding window; past reports show 7 beats in 8 quarters and an average absolute reaction of 7.2%. Over the last 90 days, Congress recorded 1 buy and 0 sales. Seasonality from this point has averaged a 10.5% gain over the next 20 trading days across 5 years, rising in 3 of them. Analyst consensus among 9 firms stands at 6 buy, 3 hold, 0 sell, with a consensus target of $54.89.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
AtriCure price vs fair value
Close $57.28200-day averageGekko Fair Value $52.18
AtriCure quick facts
- Market cap
- $2.91B
- P/E ratio
- 253.9
- Forward P/E
- 232.6
- EPS, TTM
- $0.21
- Revenue, TTM
- $569.6M
- Profit margin
- 1.9%
- Dividend yield
- —
- Beta
- 1.25
- Volume
- 645,591 avg 1.51M
- 1-year return
- +57.1%
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±8.3%
- 50-day average
- $51.08
- 200-day average
- $36.76
- Next earnings
- Nov 4 after close
- Shares outstanding
- 50.87M
AtriCure swing-trade checklist
AtriCure scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $57.28 is above the 50-day ($51.08) and 200-day ($36.76) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.8, Neutral
Reading 55.8 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
9.8% above
Price is 9.8% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+10.5% on average
From this point in the calendar, the next 20 trading days averaged +10.5% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
AtriCure stock chart and price history
AtriCure closed at $57.28 on Oct 12, 2026, +57.1% over the past year, inside a 52-week range of $25.36 to $61.70.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.0%
- 3 months
- +66.9%
- 6 months
- +99.9%
- 1 year
- +57.1%
The full ATRC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ATRC in Gekko
Follow AtriCure through every session
Put ATRC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ATRC in GekkoFree for 7 days. No credit card required.
About AtriCure
AtriCure designs and manufactures medical devices used in surgery on heart tissue and the nerves between the ribs. Its offerings center on ablation tools, including single-use radiofrequency clamps, multifunctional pens that let surgeons assess heart rhythm problems and deliver temporary pacing or stimulation alongside tissue ablation, and devices built for longer or variable-length ablation lines, among them a cryoablation system and a coagulation system aimed at persistent atrial fibrillation. The company also makes implantable clip systems and suture-based tools for closing soft tissue, plus accessories such as dissectors, placement guides, cannulas, and reusable instruments used in heart valve procedures.
AtriCure sells to surgical and cardiac care settings across the United States, Europe, Asia, and other regions, reaching customers through a mix of independent distributors and its own direct sales staff.
The company was founded in 2000 and is headquartered in Mason, Ohio. Its shares are listed on the NASDAQ under the ticker ATRC.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- atricure.com
AtriCure GekkoIndex: the smart money zone
AtriCure’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.8, in the Neutral zone, up 0.5 points over five sessions.
55.8Neutral
Up 0.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | +0.1% | −0.5% | ||
| Accumulation | 244 | 0.0% | +2.7% | ||
| Neutral (current zone) | 348 | +0.7% | +2.5% | ||
| Distribution | 48 | +2.3% | +6.9% | ||
| Selling | 1 | Too few readings yet | |||
Average ATRC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ATRC price, zone by zone.Track ATRC in Gekko
Is AtriCure stock overvalued? Gekko Fair Value
AtriCure trades 9.8% above Gekko Fair Value of $52.18, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what AtriCure shares are worth, recalculated every trading day.
$52.18
Gekko Fair Value, Oct 9, 2026
9.8% Overvalued
At the end of Aug 2026 the price was 7.8% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ATRC in Gekko
AtriCure insider and Congress trading
No open-market insider purchases were filed for AtriCure, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 11 traded Aug 20 |
From congressional disclosures, which report amounts as ranges.
Buybacks
AtriCure has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $314K
- As a share of market cap
- 0.01%
- Trailing four quarters
- $12.34M
From company filings.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold ATRC.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
AtriCure earnings: next date and track record
AtriCure reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- −$0.04
- Revenue estimate
- $151.1M
7 of 8reports beat the EPS estimate
±7.2%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- AtriCure reported Q2 2026 worldwide revenue of $154 million, representing 13% growth year-over-year, with U.S. business growing 14%. Pain Management franchise delivered 27% worldwide growth driven by cryoSPHERE MAX adoption. Open ablation revenue grew 11% worldwide. The company generated over $27 million adjusted EBITDA and $9 million net income. BoxX-NoAF clinical trial surpassed 50% enrollment with 500+ patients, targeting full enrollment of 960 patients by year-end.
- Guidance
- AtriCure expects cryoXT to contribute more meaningfully to revenue in the back half of 2026. BoxX-NoAF trial data readouts are anticipated in the first half of 2027, with full enrollment of 960 patients targeted by end of 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $0.18 est $0.00 | $153.6M est $151.8M | +4.5% |
| May 5, 2026 | $0.00 est −$0.07 | $141.2M est $139.7M | −2.7% |
| Feb 17, 2026 | $0.06 est −$0.04 | $140.5M est $139.7M | −1.2% |
| Oct 29, 2025 | −$0.01 est −$0.11 | $134.3M est $140.5M | −6.5% |
| Jul 29, 2025 | −$0.13 est −$0.15 | $136.1M est $130.2M | +5.7% |
| Apr 29, 2025 | −$0.14 est −$0.25 | $123.6M est $130.6M | −11.2% |
| Feb 12, 2025 | −$0.33 est −$0.23 | $124.3M est $121.3M | −4.6% |
| Oct 29, 2024 | −$0.17 est −$0.19 | $115.9M est $119.9M | +21.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
AtriCure stock forecast and analyst price targets
Analysts’ average 12-month price target for AtriCure is $54.89, −4.2% from the last close, from 9 firms rating the stock in the last 90 days.
$54.89consensus 12-month target, −4.2% from the last close
Now $57.28Avg $54.89
Low $36High $65
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | BTIG | $63 | +10.0% |
| Oct 2 | Freedom Capital Markets | $57 | −0.5% |
| Sep 17 | Stifel Nicolaus | $65 | +13.5% |
| Sep 2 | Needham | $64 | +11.7% |
| Aug 27 | Piper Sandler | $60 | +4.7% |
+2.5%average 20-day move after past Neutral readings
+10.5%average move over the next 20 trading days in the last 5 years
±4.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
AtriCure seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, AtriCure averaged +10.5% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 4 of 5 |
| Next 10 trading days | +0.9% | 4 of 5 |
| Next 15 trading days | +7.3% | 3 of 5 |
| Next 20 trading days | +10.5% | 3 of 5 |
| Next 30 trading days | +14.2% | 4 of 5 |
For scale, ATRC’s typical 20-trading-day move in either direction is about 8.3%.
AtriCure market cap and key statistics
AtriCure’s market cap is $2.91B, with a P/E ratio of 253.9 and revenue of $569.6M over the last twelve months.
Valuation
- Market cap
- $2.91B
- P/E ratio
- 253.9
- Forward P/E
- 232.6
- EPS, TTM
- $0.21
- Gekko Fair Value
- $52.18
Trading
- Volume
- 645,591
- Avg volume, 20 days
- 1.51M
- 52-week high
- $61.70
- 52-week low
- $25.36
- Shares outstanding
- 50.87M
Financials
- Revenue, TTM
- $569.6M
- Profit margin
- 1.9%
- Return on equity
- 2.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.25
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±8.3%
AtriCure stock news this week
Coverage of AtriCure this week reads neutral: 1 positive, 5 neutral and 2 negative headlines.
- Total equity of AtriCure, Inc. – MUN:A5ITradingView, Oct 12
- Return on assets % of AtriCure, Inc. – MUN:A5ITradingView, Oct 11
- Discipline and Rules-Based Execution in ATRC ResponseStock Traders Daily, Oct 10
- AtriCure Inc (ATRC) Stock Up 5.6% but GF Value Says Overvalued -- GF Score: 77/100GuruFocus, Oct 9
- ETFs Investing in AtriCure, Inc. StocksTradingView, Oct 9
- AtriCure stock fell 4.8 percent as analysts reset targetsAD HOC NEWS, Oct 7
AtriCure peers
AtriCure’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
AtriCure stock FAQ
What is AtriCure’s market cap?
AtriCure’s market cap is $2.91B at the Oct 12, 2026 close of $57.28, with 50.87M shares outstanding. The shares trade on a P/E ratio of 253.9.
What is the AtriCure stock forecast?
The consensus analyst 12-month price target for AtriCure is $54.89, −4.2% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is AtriCure stock overvalued or undervalued?
On Gekko’s estimate AtriCure is overvalued: the Oct 12, 2026 close of $57.28 is 9.8% above Gekko Fair Value of $52.18. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does AtriCure report earnings next?
AtriCure is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of −$0.04 per share on revenue of $151.1M. AtriCure beat the earnings estimate in 7 of its last 8 reports, moving 7.2% on average across the report.
What is AtriCure’s 52-week high and low?
AtriCure’s 52-week high is $61.70 and its 52-week low is $25.36; it closed at $57.28 on Oct 12, 2026, +57.1% over the past year. Over the last five years the shares peaked at $89.18 on Nov 5, 2021.
Is AtriCure stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See AtriCure the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.